RXRX Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

$18.91  +0.11 (0.59%)
As of 11/26/2021 13:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/18/2002
Outstanding shares:  159,525,190
Average volume:  1,294,194
Market cap:   $2,999,073,572
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    75629V104
ISIN:        US75629V1044
Sedol:      BM9FJ13
Valuation   (See tab for details)
PE ratio:   -24.82
PB ratio:   5.32
PS ratio:   290.16
Return on equity:   -24.59%
Net income %:   -1,425.23%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy